# Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

> **NCT04256941** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Anastrozole
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole
- **DRUG:** Palbociclib
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT04256941
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-31
- **Primary completion:** 2023-09-22
- **Final completion:** 2023-09-22
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Despite modifications, accrual was poor and the closed
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256941, "Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04256941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*